A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT) Meeting Abstract


Authors: Funt, S. A.; Knezevic, A.; Freeman, B. A.; Bolos, M.; Martorana, V.; Donoghue, M.; Khan, S.; Singh, H.; Bromberg, M.; Quinlan, C.; Carousso, M.; Jungbluth, A. A.; Patil, S.; Shah, N. J.; Lee, C. H.; McHugh, D. J.; Al-Ahmadie, H. A.; Feldman, D. R.
Abstract Title: A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
Meeting Title: 2023 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 41
Issue: 16 Suppl.
Meeting Dates: 2023 Jun 2-6
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2023-06-01
Language: English
DOI: 10.1200/JCO.2023.41.16_suppl.5040
PROVIDER: EBSCOhost
PROVIDER: cinahl
DOI/URL:
Notes: Meeting Abstract: 5040 -- This meeting was also held virtually -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Darren Richard Feldman
    342 Feldman
  2. Achim Jungbluth
    456 Jungbluth
  3. Chung-Han   Lee
    157 Lee
  4. Samuel Aaron Funt
    137 Funt
  5. Andrea Knezevic
    106 Knezevic
  6. Deaglan Joseph McHugh
    45 McHugh
  7. Neil Jayendra Shah
    85 Shah
  8. Mary Rose Bolos
    2 Bolos